The shares were sold at a price of $21 each, totaling $20,139. Following this transaction, Olukotun holds 35,781 shares ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for plozasiran for the treatment for familial chylomicronemia syndrome (FCS). In FCS, mutations in the ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion ...

An FDA approval later this year for Arrowhead’s plozasiran in FCS would put it in direct competition with Ionis’ Tryngolza.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...

ManaMed LLC, a global leader in orthopedic mobility and post-operative rehabilitation equipment, is thrilled to announce the launch of three groundbreaking products designed to enhance patient care.

On the eve of a historic merger between The University of Texas Health Science Center at San Antonio and The University of Texas at San Antonio, researchers from the two institutions have been honored ...

Arrowhead Pharmaceuticals said Friday that the Food and Drug Administration accepted the company's new drug application for its treatment of familial chylomicronemia syndrome, a severe and rare ...

Pharmaceuticals announced that the U.S. FDA has accepted the New Drug Application for investigational plozasiran for the ...

Arrowhead Pharmaceuticals announces FDA acceptance of NDA for plozasiran to treat familial chylomicronemia syndrome, with a target action date of Nov.

In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention ...

Plozasiran, previously known as ARO-APOC3, is an RNA interference (RNAi) therapeutic reducing the production of apolipoprotein C-III (APOC3). APOC3 is a key regulator of triglyceride metabolism – ...